Biotest Aktiengesellschaft (BIESF)
USD 30.48
(0.0%)
USD 30.48
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 127 Million EUR | 500.63% |
| 2022 | -31.7 Million EUR | 50.0% |
| 2021 | -63.4 Million EUR | -101.91% |
| 2020 | -31.4 Million EUR | -568.09% |
| 2019 | -4.7 Million EUR | -102.59% |
| 2018 | 181.3 Million EUR | 5280.0% |
| 2017 | -3.5 Million EUR | 92.36% |
| 2016 | -45.8 Million EUR | 44.48% |
| 2015 | -82.5 Million EUR | -538.83% |
| 2014 | 18.8 Million EUR | -40.51% |
| 2013 | 31.6 Million EUR | -5.41% |
| 2012 | 33.4 Million EUR | -27.93% |
| 2011 | 46.35 Million EUR | 25.46% |
| 2010 | 36.94 Million EUR | 43.92% |
| 2009 | 25.67 Million EUR | -0.27% |
| 2008 | 25.74 Million EUR | 65.84% |
| 2007 | 15.52 Million EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | -100.0% |
| 2004 | 5.85 Million EUR | 11.63% |
| 2003 | 5.24 Million EUR | -73.51% |
| 2002 | 19.79 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 9.7 Million EUR | -67.12% |
| 2024 Q1 | 29.5 Million EUR | -23.58% |
| 2023 Q3 | 114.4 Million EUR | 415.32% |
| 2023 Q4 | 38.6 Million EUR | -66.26% |
| 2023 Q2 | 22.2 Million EUR | 208.82% |
| 2023 Q1 | -20.4 Million EUR | -916.0% |
| 2023 FY | 127 Million EUR | 500.63% |
| 2022 Q3 | -14.3 Million EUR | 4.67% |
| 2022 Q4 | 2.5 Million EUR | 117.48% |
| 2022 FY | -31.7 Million EUR | 50.0% |
| 2022 Q1 | -4.9 Million EUR | 86.04% |
| 2022 Q2 | -15 Million EUR | -206.12% |
| 2021 Q4 | -35.1 Million EUR | -247.52% |
| 2021 Q1 | -14.1 Million EUR | -3625.0% |
| 2021 Q2 | -4.1 Million EUR | 70.92% |
| 2021 Q3 | -10.1 Million EUR | -146.34% |
| 2021 FY | -63.4 Million EUR | -101.91% |
| 2020 FY | -31.4 Million EUR | -568.09% |
| 2020 Q1 | -10.8 Million EUR | -500.0% |
| 2020 Q2 | -5.8 Million EUR | 46.3% |
| 2020 Q3 | -15.1 Million EUR | -160.34% |
| 2020 Q4 | 400 Thousand EUR | 102.65% |
| 2019 FY | -4.7 Million EUR | -102.59% |
| 2019 Q4 | -1.8 Million EUR | 63.27% |
| 2019 Q3 | -4.9 Million EUR | -253.13% |
| 2019 Q2 | 3.2 Million EUR | 366.67% |
| 2019 Q1 | -1.2 Million EUR | 85.54% |
| 2018 FY | 181.3 Million EUR | 5280.0% |
| 2018 Q4 | -8.3 Million EUR | -262.75% |
| 2018 Q3 | 5.1 Million EUR | -96.79% |
| 2018 Q2 | 158.8 Million EUR | 488.15% |
| 2018 Q1 | 27 Million EUR | 44.39% |
| 2017 FY | -3.5 Million EUR | 92.36% |
| 2017 Q4 | 18.7 Million EUR | 525.0% |
| 2017 Q3 | -4.4 Million EUR | -166.67% |
| 2017 Q2 | 6.6 Million EUR | 127.16% |
| 2017 Q1 | -24.3 Million EUR | 44.9% |
| 2016 Q2 | 5.9 Million EUR | 227.78% |
| 2016 Q4 | -44.1 Million EUR | -369.15% |
| 2016 Q3 | -9.4 Million EUR | -259.32% |
| 2016 FY | -45.8 Million EUR | 44.48% |
| 2016 Q1 | 1.8 Million EUR | -67.27% |
| 2015 Q3 | -85.8 Million EUR | -2283.33% |
| 2015 Q2 | -3.6 Million EUR | -357.14% |
| 2015 Q1 | 1.4 Million EUR | 1500.0% |
| 2015 FY | -82.5 Million EUR | -538.83% |
| 2015 Q4 | 5.5 Million EUR | 106.41% |
| 2014 FY | 18.8 Million EUR | -40.51% |
| 2014 Q3 | 5.5 Million EUR | -37.5% |
| 2014 Q4 | -100 Thousand EUR | -101.82% |
| 2014 Q2 | 8.8 Million EUR | 76.0% |
| 2014 Q1 | 5 Million EUR | -37.5% |
| 2013 Q4 | 8 Million EUR | -8.05% |
| 2013 FY | 31.6 Million EUR | -5.41% |
| 2013 Q2 | 8.3 Million EUR | 18.57% |
| 2013 Q1 | 7 Million EUR | -60.69% |
| 2013 Q3 | 8.7 Million EUR | 4.82% |
| 2012 FY | 33.4 Million EUR | -27.93% |
| 2012 Q2 | 6.1 Million EUR | 60.53% |
| 2012 Q3 | 5.7 Million EUR | -6.56% |
| 2012 Q4 | 17.8 Million EUR | 212.42% |
| 2012 Q1 | 3.8 Million EUR | -35.08% |
| 2011 Q2 | 7.3 Million EUR | 23.73% |
| 2011 Q4 | 5.85 Million EUR | -78.24% |
| 2011 Q3 | 26.9 Million EUR | 268.49% |
| 2011 FY | 46.35 Million EUR | 25.46% |
| 2011 Q1 | 5.9 Million EUR | -25.76% |
| 2010 Q1 | 22 Million EUR | 755.37% |
| 2010 Q4 | 7.94 Million EUR | 562.25% |
| 2010 Q2 | 7.1 Million EUR | -67.73% |
| 2010 FY | 36.94 Million EUR | 43.92% |
| 2010 Q3 | 1.2 Million EUR | -83.1% |
| 2009 FY | 25.67 Million EUR | -0.27% |
| 2009 Q4 | 2.57 Million EUR | -69.38% |
| 2009 Q3 | 8.4 Million EUR | 10.53% |
| 2009 Q2 | 7.6 Million EUR | 7.04% |
| 2009 Q1 | 7.1 Million EUR | 0.0% |
| 2008 FY | 25.74 Million EUR | 65.84% |
| 2007 FY | 15.52 Million EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | -100.0% |
| 2004 FY | 5.85 Million EUR | 11.63% |
| 2003 FY | 5.24 Million EUR | -73.51% |
| 2002 FY | 19.79 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 269.417% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 2031.233% |
| SQZ Biotechnologies Company | -79.46 Million USD | 259.821% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -139.718% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -94.986% |
| Mesoblast Limited | -87.95 Million USD | 244.39% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 7075.998% |
| Genus plc | 7.9 Million USD | -1507.595% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 1266.021% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 3522.965% |
| Marizyme, Inc. | -65.34 Million USD | 294.347% |
| ContraFect Corporation | -65.15 Million USD | 294.926% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 1536.002% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 2699.23% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 7451.856% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 4490.826% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 1675.745% |
| MultiCell Technologies, Inc. | -380.07 USD | 33414997.256% |
| Accustem Sciences Inc. | -3.74 Million USD | 3489.904% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 345.686% |
| EV Biologics, Inc. | -1.26 Million USD | 10122.618% |
| Q BioMed Inc. | -2.05 Million USD | 6288.803% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 3502.089% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 20182.004% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 5434.185% |
| Biomind Labs Inc. | -1.21 Million USD | 10558.537% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 1304.02% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 1706.966% |
| Skye Bioscience, Inc. | -37.64 Million USD | 437.364% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 5953.036% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 848123.504% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 1918.745% |
| IMV Inc. | -36.48 Million USD | 448.082% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 900.179% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 2283.161% |
| GB Sciences, Inc. | -1.36 Million USD | 9426.735% |
| Alpha Cognition Inc. | -13.77 Million USD | 1022.123% |
| HST Global, Inc. | -146.21 Thousand USD | 86961.364% |
| CSL Limited | 2.64 Billion USD | 95.193% |
| Halberd Corporation | -79.67 Thousand USD | 159495.552% |
| Enzolytics Inc. | -2.17 Million USD | 5934.166% |
| Resverlogix Corp. | -3.61 Million USD | 3618.006% |
| Affymax, Inc. | -14.42 Million USD | 980.477% |
| SYBLEU INC | -180.3 Thousand USD | 70536.596% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 4104.495% |
| argenx SE | -295.05 Million USD | 143.043% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 302.879% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -129491.837% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 3296.583% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 4296.772% |
| AVAX Technologies, Inc. | -6.41 Million USD | 2080.152% |
| Zenith Capital Corp. | -10.59 Million USD | 1298.565% |
| Genscript Biotech Corporation | -95.47 Million USD | 233.016% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 546524.576% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 3163.241% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 210223.624% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 312.64% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 4194.439% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | 12125.866% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 6615.33% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 3425.478% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 6433.801% |
| BioStem Technologies, Inc. | -8.48 Million USD | 1597.115% |
| ONE Bio Corp. | 8.67 Million USD | -1363.705% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 28874.11% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 9610.038% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 7337.412% |
| Agentix Corp. | -1.37 Million USD | 9341.667% |
| LadRx Corporation | 400.44 Thousand USD | -31614.876% |
| Cell Source, Inc. | -5.32 Million USD | 2486.674% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 30667.129% |
| Regen BioPharma, Inc. | 1.02 Million USD | -12308.306% |
| Regen BioPharma, Inc. | 1.02 Million USD | -12308.306% |
| NovAccess Global Inc. | -4.76 Million USD | 2762.928% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -1734.043% |
| Itoco Inc. | -1.86 Million USD | 6895.096% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 2958.728% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 7709.347% |
| Kadimastem Ltd | -3.3 Million USD | 3939.877% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 46551.745% |
| CytoDyn Inc. | -49.84 Million USD | 354.81% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 160792.369% |
| Mobile Lads Corp. | -2.26 Million USD | 5711.295% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 55770.745% |
| Qrons Inc. | -789.34 Thousand USD | 16189.248% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 13588.698% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 6183.302% |
| Rebus Holdings, Inc. | -1.02 Million USD | 12550.98% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 7974.812% |
| International Stem Cell Corporation | -131 Thousand USD | 97046.565% |
| Bioxytran, Inc. | -4.28 Million USD | 3067.288% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 234106.486% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 5119.273% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 364.187% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 6107.569% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 16363.557% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 4108.838% |
| Neutra Corp. | -233.46 Thousand USD | 54497.875% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 725.893% |
| PureTech Health plc | -65.69 Million USD | 293.312% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 697.182% |
| IXICO plc | -1.17 Million USD | 10880.985% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 1379.339% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 322.308% |
| CSL Limited | 2.64 Billion USD | 95.193% |
| Cellectis S.A. | -103.17 Million USD | 223.093% |